This “Atopic Keratoconjunctivitis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Atopic Keratoconjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Atopic Keratoconjunctivitis Understanding
Atopic keratoconjunctivitis (AKC) is the result of a condition called "atopy". Atopy is a genetic condition where immune system produces higher than normal antibodies in response to a given allergen. With AKC, the conjunctiva lining the eyelids is usually red and swollen. The lower eyelid generally is affected more than the upper eyelid. This is a differentiating symptom from vernal keratoconjunctivitis where the upper eyelid is most often affected. If left untreated, AKC can progress to ulceration, scarring, cataract, keratoconus, and corneal vascularization. AKC is a multifactorial disease with genetic and environmental risk factors. The strongest associations are genetic predisposition for poor skin barrier function and dysregulation of the immune system, asthma, allergic rhinitis and environmental allergens. The diagnosis of atopic keratoconjunctivitis is largely clinical, relying on history and exam findings. The purpose of treatment in AKC is to improve symptoms, limit exacerbations and prevent complications/sequelae that lead to vision loss. It is also important to balance this with limiting side effects of treatment. Systemic antihistamines are routinely used in atopic disease.
"Atopic Keratoconjunctivitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atopic Keratoconjunctivitis pipeline landscape is provided which includes the disease overview and Atopic Keratoconjunctivitis treatment guidelines. The assessment part of the report embraces, in depth Atopic Keratoconjunctivitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Keratoconjunctivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Keratoconjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Keratoconjunctivitis.
This segment of the Atopic Keratoconjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor. By blocking the IL-4R alpha subunit, dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and immunoglobulin E. The company has initiated Phase II double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
This segment of the report provides insights about the different Atopic Keratoconjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Atopic Keratoconjunctivitis. The companies which have their Atopic Keratoconjunctivitis drug candidates in the most advanced stage, i.e. Phase II include, Regeneron Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atopic Keratoconjunctivitis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Keratoconjunctivitis drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Atopic Keratoconjunctivitis Understanding
Atopic Keratoconjunctivitis: Overview
Atopic keratoconjunctivitis (AKC) is the result of a condition called "atopy". Atopy is a genetic condition where immune system produces higher than normal antibodies in response to a given allergen. With AKC, the conjunctiva lining the eyelids is usually red and swollen. The lower eyelid generally is affected more than the upper eyelid. This is a differentiating symptom from vernal keratoconjunctivitis where the upper eyelid is most often affected. If left untreated, AKC can progress to ulceration, scarring, cataract, keratoconus, and corneal vascularization. AKC is a multifactorial disease with genetic and environmental risk factors. The strongest associations are genetic predisposition for poor skin barrier function and dysregulation of the immune system, asthma, allergic rhinitis and environmental allergens. The diagnosis of atopic keratoconjunctivitis is largely clinical, relying on history and exam findings. The purpose of treatment in AKC is to improve symptoms, limit exacerbations and prevent complications/sequelae that lead to vision loss. It is also important to balance this with limiting side effects of treatment. Systemic antihistamines are routinely used in atopic disease.
"Atopic Keratoconjunctivitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atopic Keratoconjunctivitis pipeline landscape is provided which includes the disease overview and Atopic Keratoconjunctivitis treatment guidelines. The assessment part of the report embraces, in depth Atopic Keratoconjunctivitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Keratoconjunctivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Keratoconjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Keratoconjunctivitis.
Atopic Keratoconjunctivitis Emerging Drugs Chapters
This segment of the Atopic Keratoconjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atopic Keratoconjunctivitis Emerging Drugs
Dupilumab: Regeneron Pharmaceuticals
Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor. By blocking the IL-4R alpha subunit, dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and immunoglobulin E. The company has initiated Phase II double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Atopic Keratoconjunctivitis: Therapeutic Assessment
This segment of the report provides insights about the different Atopic Keratoconjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Atopic Keratoconjunctivitis
There are approx. 5+ key companies which are developing the therapies for Atopic Keratoconjunctivitis. The companies which have their Atopic Keratoconjunctivitis drug candidates in the most advanced stage, i.e. Phase II include, Regeneron Pharmaceuticals.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Atopic Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Atopic Keratoconjunctivitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atopic Keratoconjunctivitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Keratoconjunctivitis drugs.
Atopic Keratoconjunctivitis Report Insights
- Atopic Keratoconjunctivitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Atopic Keratoconjunctivitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Atopic Keratoconjunctivitis drugs?
- How many Atopic Keratoconjunctivitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Keratoconjunctivitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atopic Keratoconjunctivitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atopic Keratoconjunctivitis and their status?
- What are the key designations that have been granted to the emerging drugs?
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Atopic Keratoconjunctivitis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Dupilumab: Regeneron Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I/II)
- Comparative Analysis
TX200-TR101: Sangamo therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Atopic Keratoconjunctivitis Key Companies
Atopic Keratoconjunctivitis Key Products
Atopic Keratoconjunctivitis- Unmet Needs
Atopic Keratoconjunctivitis- Market Drivers and Barriers
Atopic Keratoconjunctivitis- Future Perspectives and Conclusion
Atopic Keratoconjunctivitis Analyst Views
Atopic Keratoconjunctivitis Key Companies
AppendixList of Tables
Table 1 Total Products for Atopic Keratoconjunctivitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Atopic Keratoconjunctivitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Regeneron Pharmaceuticals
- Allakos
- Akari Therapeutics
- NexEos Bio
- Aldeyra therapeutics
